A comparative study of 24-hour and 6-hour Infusion of Nafamostat Mesilate for Prevention of Post-ERCP Pancreatitis
Not Applicable
Completed
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0001625
- Lead Sponsor
- Pusan National University Yangsan Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 256
Inclusion Criteria
All patients with an intact papilla and known or suspected pancreatobiliary disease, who are candidates for therapeutic or diagnostic biliary ERCP at a single tertiary referral center (Pusan National University Yangsan Hospital), were scheduled to participate in the study.
Exclusion Criteria
Patients were excluded for any of the following reasons: age younger than 18 years, previous history of precut or biliary sphicterotomy, previous history of biliary or pancreatic stenting, repeated ERCP, clinical evidence of acute pancreatitis at the time of procedure, treatment with nafamostat mesilate or other protease inhibitors in the last 7 days, pregnancy and refusal to participate.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method post ERCP pancreatitis incidence, post ERCP pancreatitis severity, serum amylase/lipase level, abdominal pain
- Secondary Outcome Measures
Name Time Method diagnostic procedures, therapeutic procedures, examination time, and number of injection or cannulation of the pancreatic duct, placement of prophylactic pancreatic stent